Rheumatology, Dermatology, Gastroenterology, Respiratory & ENT
Rheumatologic diseases affect an estimated 54 million patients in the U.S alone and represent a leading cause of disability. The introduction of innovative medicines continues to reduce patient burden of disease.
Axial Spondyloarthritis
Giant Cell Arteritis
Juvenile Idiopathic Arthritis
Lupus Nephritis
Psoriatic Arthritis
Rheumatoid Arthritis
Systemic Lupus Erthematosus
Clinical Effectiveness in PsA
Burden of Illness - Depression in RA Patients
Evaluate the Natural History of Patients with PsO that Transition to PsA
Understand the Role Patient Subtype Plays in PsA Treatment Selection
Understand the Role of Race in Response to hydroxychloroquine Treatment in SLE
Dermatology conditions affect millions of patients and result in hundreds of millions of dollars in loss of productivity every year. Yet, despite increased development of new treatments, high quality research-driven insights to enable market adoption, understanding of safety and effectiveness profiles, broadening of payer coverage, and increased access to care have been difficult to attain.
DataDermTM is the world’s largest clinical data registry of patients receiving dermatologic care.
Atopic Dermatitis
Alopecia Areata
Hidradenitis Suppurativa
Psoriasis
Vitiligo
Assess the potential positive cardiometabolic effects of specific psoriasis drug treatments in patients
Evaluate the natural history of patients with PsO that transition to PsA
Identify biologic-eligible patients, Hurley Stage 2 or 3 in HS
Treatment effectiveness by patient subtype in psoriasis patients
Understand a Patient's Clinical Journey
Ulcerative Colitis (UC) and Crohn’s Disease (CD) are the two main types of Inflammatory Bowel Disease (IBD), which affect up to 3 million people in the U.S. alone. UC and CD are lifelong conditions that cause chronic inflammation in the intestines, leading to pain and a variety of symptoms in those affected. These conditions can impact any age or gender. Research continues around root causes, diagnosis, and best treatment protocols. The OM1 PremiOM UC and CD datasets look to support these research efforts.
Ulcerative Colitis
Crohn’s Disease
Assess the impact of changes in the management of UC patients who have an incomplete response to TNFa therapy
Leverage observed and calculated CDAI scores in patients with Crohn’s Disease to understand response to therapy
Chronic rhinosinusitis (CRNS) is an inflammatory condition of the paranasal sinuses that most often causes chronic sinonasal symptoms. In the U.S., chronic rhinosinusitis has an estimated prevalence of 1% to 5%. It is a readily treatable disease that is responsible for direct and indirect health care expenses totaling billions of dollars every year in the United States.
Asthma is one of the most common and costly diseases in the United States, affecting approximately 25 million people. There is no cure for asthma, but appropriate treatment prevents asthma attacks and can improve quality of life. The burden of asthma in the United States falls disproportionately on people with low-income, senior adults, and minority populations.
Impact of Steroid-eluting Implants on HCRU among CRS Patients Undergoing Sinus Surgery
Asthma: Harmonized outcome measures for use in asthma patient registries and clinical practice
Reg-entSM is the first and only national repository of otolaryngology-specific data.
Dr. Richard Gliklich, MD is the CEO of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles.
Dr. Gliklich is well known in the areas of registries, outcomes and analytics. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook “Registries for Evaluating Patient Outcomes: A User’s Guide” and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement.
He has led several key national and international efforts focused on evaluating the safety, effectiveness, value and quality of healthcare. Dr. Gliklich also holds several patents for both health outcomes systems and medical devices. Dr. Gliklich is a graduate of Yale University and Harvard Medical School and a former Charles A. Dana Scholar at the University of Pennsylvania. He is also a surgeon and the Leffenfeld Professor at Harvard Medical School.
